A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis



Status:Terminated
Conditions:Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Healthy:No
Age Range:50 - 79
Updated:4/21/2016
Start Date:October 2012
End Date:January 2016

Use our guide to learn which trials are right for you!

To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary
function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a
chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.

The primary objective of this study is to determine the effect of multiple doses of
tralokinumab on pulmonary function in adults with mild to moderate IPF

Key Inclusion Criteria:

- 1) IPF diagnosis for ≤ 5 years prior to Visit 1 (screening). Confirmation of
diagnosis of IPF in accordance is required for subject inclusion 2) Confirmed
diagnosis of IPF by clinical characteristics, HRCT and surgical lung biopsy (if
required) 3)Mild to moderate IPF to include all of the following at screening:

1. FVC ≥ 50% predicted normal

2. Partial pressure of oxygen in arterial blood (PaO2) of ≥ 55 mmHg on room air or
50 mmHg at high altitude (> 1500 meters), or oxygen saturation by pulse oximetry
(SpO2) of ≥ 90%on room air at rest

3. Hemoglobin-corrected diffusion capacity for carbon monoxide (DLCO) ≥ 30%
predicted normal 4) Be able to walk ≥ 100 meters unassisted

Key Exclusion Criteria:

1. A FEV1/FVC ratio less than 0.70 at the time of screening (postbronchodilator)

2. The extent of emphysema on the HRCT is greater than the extent of fibrosis.

3. Currently listed for lung transplantation

4. Use of the following medications:

1. Immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine,
intramuscular long-acting depot corticosteroid) within 3 months prior to Visit 1
(screening). Oral prednisone ≤ 15 mg/day (or equivalent oral corticosteroid) is
allowed for chronic use if subject was on a stable dose at least 30 days prior
to Visit 1 (screening)

2. Pirfenidone within 4 weeks prior to Visit 1 (screening)

3. N-acetylcysteine within 4 weeks prior to Visit 1 (screening)

4. Live attenuated vaccines within 4 weeks prior to Visit 1 (screening)
We found this trial at
22
sites
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Box Hill,
Click here to add this to my saved trials
Charleston, South Carolina 29412
?
mi
from
Charleston, SC
Click here to add this to my saved trials
?
mi
from
Chesterfield, MO
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Hershey, PA
Click here to add this to my saved trials
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
McAllen, TX
Click here to add this to my saved trials
?
mi
from
McKinney, TX
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
?
mi
from
Summit, NJ
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Winter Park, FL
Click here to add this to my saved trials